Insulet (NASDAQ:PODD) Given New $167.00 Price Target at Leerink Partners

Posted by Geri Gentry on Nov 5th, 2026

Insulet (NASDAQ:PODD – Get Free Report) had its target price upped by stock analysts at Leerink Partners from $143.00 to $167.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has a “market perform” rating on the medical instruments supplier’s stock. Leerink Partners‘s price objective would suggest a potential upside of 8.08% from the stock’s current price.

Several other analysts have also recently commented on PODD. TD Cowen restated a “hold” rating on shares of Insulet in a research note on Wednesday. Raymond James Financial reiterated an “outperform” rating and set a $180.00 price target on shares of Insulet in a research note on Thursday, August 6th. Truist Financial lowered shares of Insulet from a “buy” rating to a “hold” rating and dropped their price target for the stock from $210.00 to $153.00 in a research note on Wednesday, August 5th. Weiss Ratings reissued a “sell (d+)” rating on shares of Insulet in a report on Monday, September 21st. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $200.00 price target on shares of Insulet in a report on Wednesday. Thirteen equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $190.88.

Get Our Latest Stock Report on Insulet

Insulet Stock Performance

Shares of Insulet stock traded down $10.51 during trading hours on Thursday, hitting $154.51. 843,811 shares of the company were exchanged, compared to its average volume of 1,395,500. Insulet has a 1 year low of $126.40 and a 1 year high of $354.88. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The business has a 50-day moving average of $141.65 and a 200-day moving average of $178.00. The stock has a market capitalization of $10.72 billion, a price-to-earnings ratio of 28.85, a P/E/G ratio of 1.22 and a beta of 1.06.

Insulet (NASDAQ:PODD – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.59 by $0.40. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The firm had revenue of $842.00 million during the quarter, compared to the consensus estimate of $832.63 million. During the same period last year, the company earned $1.24 earnings per share. The company’s revenue for the quarter was up 19.2% on a year-over-year basis. As a group, analysts expect that Insulet will post 6.51 EPS for the current fiscal year.

Institutional Trading of Insulet

Several hedge funds and other institutional investors have recently bought and sold shares of PODD. BlackRock Inc. acquired a new stake in shares of Insulet during the second quarter worth $1,018,582,000. Arrowstreet Capital Limited Partnership increased its position in Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after purchasing an additional 1,011,369 shares during the last quarter. Man Group plc purchased a new position in Insulet during the second quarter worth approximately $78,746,000. Bank of America Corp DE purchased a new position in Insulet during the second quarter worth approximately $64,921,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Insulet in the 2nd quarter valued at $60,615,000.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

Positive Sentiment: Insulet reported Q3 adjusted EPS of $1.99 versus $1.59 expected and revenue of $842 million versus $832.6 million expected. Revenue grew 19.2% year over year, and reports noted margin expansion and a stronger 2026 outlook, though the full-year EPS outlook was maintained. Insulet Q3 Earnings and Revenues Surpass Estimates
Positive Sentiment: The company announced a $1 billion share repurchase program, which may support per-share value and signal confidence in its business outlook. Insulet Announces $1 Billion Equity Buyback
Positive Sentiment: Several firms raised their price targets: Bernstein to $200 with an Outperform rating, RBC to $180 with Outperform, and Wells Fargo to $172. RBC Raises Insulet Price Target
Neutral Sentiment: UBS also lifted its target, to $171 from $150, but kept a Neutral rating—recognizing improved prospects without signaling a stronger recommendation. UBS Adjusts Insulet Price Target
Negative Sentiment: Management expects slower growth in 2027 and anticipates rivals taking some share from its Omnipod product. Those concerns may temper enthusiasm after the earnings beat and help explain why the stock is lower in Thursday trading. CEO Sees Slower Growth and Competition

About Insulet

(Get Free Report)

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.